Standard of Care Drugs for the 10 Most Common Cancers
------------------------------------------------------

1. Breast Cancer
   - Hormonal: Tamoxifen, Letrozole, Anastrozole, Exemestane
   - CDK4/6 Inhibitors: Palbociclib, Ribociclib, Abemaciclib
   - HER2+: Trastuzumab, Pertuzumab, T-DM1, T-DXd (Enhertu)
   - Chemotherapy: Paclitaxel, Carboplatin
   - Immunotherapy (TNBC): Pembrolizumab, Atezolizumab

2. Lung Cancer (NSCLC & SCLC)
   - Targeted: Osimertinib (EGFR), Alectinib, Lorlatinib (ALK)
   - Chemotherapy: Carboplatin, Cisplatin, Pemetrexed, Paclitaxel, Etoposide
   - Immunotherapy: Pembrolizumab, Atezolizumab, Durvalumab

3. Colorectal Cancer
   - Chemotherapy: 5-FU, Leucovorin, Oxaliplatin, Irinotecan
   - Targeted: Cetuximab, Panitumumab (RAS wild-type), Bevacizumab

4. Prostate Cancer
   - Hormonal: Leuprolide, Goserelin, Abiraterone, Enzalutamide, Apalutamide
   - Chemotherapy (CRPC): Docetaxel, Cabazitaxel

5. Stomach (Gastric) Cancer
   - Chemotherapy: 5-FU, Cisplatin, Oxaliplatin, Capecitabine
   - HER2+: Trastuzumab
   - Immunotherapy (PD-L1+): Nivolumab

6. Liver Cancer (Hepatocellular Carcinoma)
   - Immunotherapy + Anti-VEGF: Atezolizumab + Bevacizumab
   - Other Targeted: Sorafenib, Lenvatinib, Regorafenib, Cabozantinib

7. Cervical Cancer
   - Chemotherapy: Cisplatin, Paclitaxel
   - Targeted: Bevacizumab
   - Immunotherapy (PD-L1+): Pembrolizumab

8. Esophageal Cancer
   - Chemotherapy: 5-FU, Cisplatin, Paclitaxel, Carboplatin
   - Immunotherapy (PD-L1+ or adjuvant): Nivolumab

9. Thyroid Cancer
   - RAI-sensitive: Radioactive iodine, Levothyroxine
   - RAI-refractory: Lenvatinib, Sorafenib
   - Medullary: Vandetanib, Cabozantinib
   - Anaplastic (BRAF+): Dabrafenib + Trametinib

10. Bladder Cancer
    - Chemotherapy: Cisplatin + Gemcitabine
    - Immunotherapy (advanced): Atezolizumab, Nivolumab
    - ADC: Enfortumab Vedotin
"""
